Evidence map›Paper›PMID 39508861›Full record

Observational studyJournal of bone and mineral metabolism2025

Aromatase inhibitors, bone microstructure, and estimated bone strength in postmenopausal women with breast cancer: a 5-year prospective study.

Sayaka Kuba, Ko Chiba, Kounosuke Watanabe, Megumi Matsumoto, Michi Morita, Momoko Akashi, Aki Yukutake, Yuki Hara, Ayako Fukushima, Eiko Inamasu and 6 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of bone and mineral metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sayaka KubaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto-Machi, Nagasaki, 852-8501, Japan. skuba@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0002-0225-099X
Ko ChibaDepartment of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Kounosuke WatanabeDepartment of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Megumi MatsumotoDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Michi MoritaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto-Machi, Nagasaki, 852-8501, Japan.
Momoko AkashiDepartment of Surgery, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto-Machi, Nagasaki, 852-8501, Japan.
Aki YukutakeDepartment of Surgery, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto-Machi, Nagasaki, 852-8501, Japan.
Yuki HaraDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Ayako FukushimaDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Eiko InamasuDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Ryota OtsuboDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Kosho YamanouchiDepartment of Surgery, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto-Machi, Nagasaki, 852-8501, Japan.
Kengo KanetakaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto-Machi, Nagasaki, 852-8501, Japan.
Makoto OsakiDepartment of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Keitaro MatsumotoDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Susumu EguchiDepartment of Surgery, Nagasaki University Graduate School of Biomedical Science, 1-7-1 Sakamoto-Machi, Nagasaki, 852-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAromatase inhibitors (AIs) are the standard treatment for early breast cancer (EBC) and are typical causative agents of cancer treatment-induced bone loss. However, the effects of long-term treatment with these drugs on bone microstructure remain unclear. MATERIALS AND

methodsThis prospective, single-arm observational study included postmenopausal, non-osteoporotic women with hormone receptor-positive EBC. Patients who underwent dual-energy X-ray absorptiometry (DXA), high-resolution peripheral quantitative computed tomography (HR-pQCT), and tartrate-resistant acid phosphatase-5b (TRACP-5b) or procollagen type I N-terminal propeptide levels were compared at baseline and at 60 months after commencing AI treatment.

resultsFifteen women were included in the study, with a median age of 58 years and a quartile range of 56.5-62.5 years. At 60 months, HR-pQCT revealed that the cortical area and thickness decreased with increased cortical porosity in the cortical bone. In addition, the number of trabeculae decreased and trabecular separation increased trabecular bones decreases, and trabecular bone separation opens, resulting in a decrease in the trabecular bone volume fraction. Total bone mineral density (BMD), trabecular volumetric BMD, and cortical volumetric BMD, and estimated bone strength significantly decreased. DXA BMD values significantly decreased in the total hip and femoral neck but not the lumbar spine. TRACP-5b values after 5 years of AI treatment showed a significant negative correlation with the rate of change in the total volumetric BMD in the distal tibia.

conclusionPostmenopausal women who received AIs for 5 years for EBC experienced significant deterioration in the bone microstructure, BMD, and estimated bone strength.

Indexed as

Aromatase InhibitorsBone and BonesBone DensityBreast NeoplasmsPostmenopauseAbsorptiometry, PhotonFemaleHumansMiddle AgedProspective StudiesTomography, X-Ray ComputedAromatase InhibitorsAromatase inhibitorsBone microstructureBreast cancerCortical boneHigh-resolution peripheral quantitative computed tomography (HR-pQCT)Trabecular bone

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.